Zilico & Zedscan

Zilico

Zilico was founded in 2006 following a successful collaboration between the University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust, UK, to develop a more accurate means of diagnosis for cervical intraepithelial neoplasia (CIN).

The company has developed its patented Electrical Impedance Spectroscopy (EIS) into a platform technology for cancer diagnosis and is expanding its product development into other clinical areas.

 

Zedscan

ZedScan is a diagnostic system that is used alongside colposcopy to provide an objective assessment of the cervical epithelial tissue in real time.

Clinical Benefits of Using ZedScan

When used alongside colposcopy ZedScan has demonstrated greater accuracy in detecting cervical disease.

Increased sensitivity

  • More patients with cervical disease are detected
  • Patients who test negative for disease can confidently be released back to routine cervical screening

Increased specificity

  • Better differentiation between high grade and low grade cervical abnormalities
  • Potential to move to See & Treat for CIN2/3 diagnosis
  • ​Confidence to treat patients identified with high grade neoplasia (HG CIN)
  • Reduce the risk of over-treatment due to higher positive predictive value (PPV) than colposcopy alone
  • Reduce patient anxiety by offering treatment immediately

​Pin-point the location of pre-cancerous lesions

  • Identify the most suitable position on the cervix to take a biopsy
  • Minimise the number of biopsies taken to one per patient
  • Limit patient discomfort and co- morbidity

 

 

The list of attendees is below:

  • Organiser:

Ann Marie Sanderson

 

  • Presenters:

Darren Neill

Mary Martin

 

  • Attendees:

Brian O`Kane

Alan Stead

Stephen Alexander

Brian Lynskey

Lynn Burger

Alistair Harvey

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.